These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 16183407

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Immuno-allergic accidents with rifamipcin].
    Flageul B, Wagner L, Cottenot F.
    Acta Leprol; ; 12(2):71-8. PubMed ID: 12136739
    [Abstract] [Full Text] [Related]

  • 3. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR, Shrestha K, Pandey B, Walker SL.
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [Abstract] [Full Text] [Related]

  • 4. Multidrug therapy regimen for leprosy.
    Firooz A.
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract] [Full Text] [Related]

  • 5. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
    Alves-Rodrigues EN, Ribeiro LC, Silva MD, Takiuchi A, Fontes CJ.
    Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
    [Abstract] [Full Text] [Related]

  • 6. Dapsone drug resistance in the MDT era.
    Roche PW, Neupane KD, Failbus SS, Butlin CR.
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract] [Full Text] [Related]

  • 7. [New WHO recommendations for the treatment of leprosy].
    Acta Leprol; 1997 Sep; 10(4):189. PubMed ID: 9527754
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dapsone syndrome: an incomplete form.
    Jaswal R, Thami GP, Kanwar AJ.
    Indian J Lepr; 1998 Sep; 70(2):229-30. PubMed ID: 9724867
    [No Abstract] [Full Text] [Related]

  • 10. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B, Shrestha K, Lewis J, Hawksworth RA, Walker SL.
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [Abstract] [Full Text] [Related]

  • 11. [Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].
    Sansarricq H.
    Acta Leprol; 1986 Jul; 4(3):355-62. PubMed ID: 3551474
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
    Bucaretchi F, Vicente DC, Pereira RM, Tresoldi AT.
    Rev Inst Med Trop Sao Paulo; 2004 Jul; 46(6):331-4. PubMed ID: 15654479
    [Abstract] [Full Text] [Related]

  • 16. A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy.
    Ganapati R, Pai VV, Banerji U, Thomas J, Saha B.
    Int J Lepr Other Mycobact Dis; 1997 Dec; 65(4):495-7. PubMed ID: 9465161
    [No Abstract] [Full Text] [Related]

  • 17. [Combination chemotherapy in leprosy].
    Leiker DL.
    Ned Tijdschr Geneeskd; 1986 Oct 25; 130(43):1926-9. PubMed ID: 3774040
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
    Queiroz RH, Souza AM, Melchior E, Gouveia EG, Carvalho D.
    Lepr Rev; 1997 Sep 25; 68(3):212-7. PubMed ID: 9364821
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.